CompaniesGATT Technologies

GATT Technologies

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

4

As Collaborator

0

Total Enrollment

270

By Phase

NA: 3PHASE2: 1

By Status

COMPLETED: 3ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details

Recent Trials

NCT05900037Lead Sponsor
GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery
NAActive, not recruiting
53 participants
Started: Oct 6, 2023 · Completed: Oct 11, 2025
NCT05385952Lead Sponsor
GATT-Patch Versus TachoSil in Liver Surgery
NACompleted
131 participants
Started: Aug 4, 2022 · Completed: May 10, 2024
NCT04819945Lead Sponsor
Clinical Safety and Performance of GATT-Patch in Open Liver Surgery
NACompleted
56 participants
Started: Apr 16, 2021 · Completed: Feb 24, 2022
NCT00457288Lead Sponsor
Efficacy and Safety of TF002 in Cutaneous Mastocytosis
PHASE2Completed
30 participants
Started: Apr 30, 2007 · Completed: Sep 30, 2007
Related Companies
Ethicon
acquired